Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications.

Zito Marino F, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F, Rossi G, Franco R.

Int J Med Sci. 2019 Jun 10;16(7):981-989. doi: 10.7150/ijms.34739. eCollection 2019. Review.

2.

Adequacy of Cytologic Samples by Ultrasound-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology of Peripheral Pulmonary Nodules for Morphologic Diagnosis and Molecular Evaluations: Comparison With Computed Tomography-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology.

Cozzolino I, Ronchi A, Messina G, Montella M, Morgillo F, Vicidomini G, Tirino V, Grimaldi A, Marino FZ, Santini M, Cappabianca S, Franco R.

Arch Pathol Lab Med. 2019 Jul 22. doi: 10.5858/arpa.2018-0346-OA. [Epub ahead of print]

PMID:
31329477
3.

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.

Morabito A, Piccirillo MC, Maione P, Luciani A, Cavanna L, Bonanno L, Filipazzi V, Leo S, Cinieri S, Morgillo F, Burgio MA, Ferrara D, Rosetti F, Bianco R, Artioli F, Cortinovis D, Gebbia V, Fregoni V, Mencoboni M, Sandomenico C, Rossi A, Montanino A, Manzo A, Rocco G, Arenare L, Daniele G, Signoriello S, Gallo C, Perrone F, Gridelli C.

Lung Cancer. 2019 Jul;133:62-68. doi: 10.1016/j.lungcan.2019.05.009. Epub 2019 May 9.

PMID:
31200830
4.

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.

Della Corte CM, Barra G, Ciaramella V, Di Liello R, Vicidomini G, Zappavigna S, Luce A, Abate M, Fiorelli A, Caraglia M, Santini M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1.

5.

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.

Belli V, Matrone N, Napolitano S, Migliardi G, Cottino F, Bertotti A, Trusolino L, Martinelli E, Morgillo F, Ciardiello D, De Falco V, Giunta EF, Bracale U, Ciardiello F, Troiani T.

J Exp Clin Cancer Res. 2019 Jun 4;38(1):236. doi: 10.1186/s13046-019-1230-z.

6.

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC.

Ciaramella V, Sasso FC, Di Liello R, Corte CMD, Barra G, Viscardi G, Esposito G, Sparano F, Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F.

J Exp Clin Cancer Res. 2019 Apr 26;38(1):178. doi: 10.1186/s13046-019-1176-1.

7.

Early use of steroids affects immune cells and impairs immunotherapy efficacy.

Della Corte CM, Morgillo F.

ESMO Open. 2019 Feb 27;4(1):e000477. doi: 10.1136/esmoopen-2018-000477. eCollection 2019. No abstract available.

8.

Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis.

D'Abrosca B, Ciaramella V, Graziani V, Papaccio F, Della Corte CM, Potenza N, Fiorentino A, Ciardiello F, Morgillo F.

Sci Rep. 2019 Mar 21;9(1):4986. doi: 10.1038/s41598-019-41372-1.

9.

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.

Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, Della Corte CM, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, Sibilia M, Ciardiello F, Martinelli E.

Mol Cancer Ther. 2019 Apr;18(4):845-855. doi: 10.1158/1535-7163.MCT-18-0539. Epub 2019 Mar 1.

PMID:
30824612
10.

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.

Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E.

J Exp Clin Cancer Res. 2019 Jan 28;38(1):41. doi: 10.1186/s13046-019-1035-0.

11.

ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer.

Della Corte CM, Gay CM, Byers LA, Morgillo F.

EBioMedicine. 2019 Jan;39:5-6. doi: 10.1016/j.ebiom.2018.12.008. Epub 2018 Dec 13. No abstract available.

12.

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.

Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F.

Tumour Biol. 2018 Nov;40(11):1010428318815047. doi: 10.1177/1010428318815047.

PMID:
30486741
13.

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.

Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F.

Int J Mol Sci. 2018 Nov 14;19(11). pii: E3595. doi: 10.3390/ijms19113595. Review.

14.

Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.

Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F.

Breast. 2018 Oct;41:165-171. doi: 10.1016/j.breast.2018.08.002. Epub 2018 Aug 4.

PMID:
30103105
15.

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F.

Gastroenterol Res Pract. 2018 Jun 10;2018:2373868. doi: 10.1155/2018/2373868. eCollection 2018.

16.

It is finally time for adjuvant therapy in melanoma.

Napolitano S, Brancaccio G, Argenziano G, Martinelli E, Morgillo F, Ciardiello F, Troiani T.

Cancer Treat Rev. 2018 Sep;69:101-111. doi: 10.1016/j.ctrv.2018.06.003. Epub 2018 Jun 9. Review.

PMID:
29957365
17.

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota.

Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A.

Neoplasia. 2018 Jul;20(7):721-733. doi: 10.1016/j.neo.2018.05.002. Epub 2018 May 30. Review. No abstract available.

18.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F.

Oncotarget. 2018 Apr 10;9(27):19273-19282. doi: 10.18632/oncotarget.25018. eCollection 2018 Apr 10.

19.

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives.

Ciaramella V, Della Corte CM, Ciardiello F, Morgillo F.

Front Endocrinol (Lausanne). 2018 Mar 27;9:115. doi: 10.3389/fendo.2018.00115. eCollection 2018. Review.

20.

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8.

21.

Role and targeting of anaplastic lymphoma kinase in cancer.

Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. Review.

22.

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.

Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T.

ESMO Open. 2017 Jul 29;2(3):e000177. doi: 10.1136/esmoopen-2017-000177. eCollection 2017.

23.

Primary pleural squamous cell carcinoma: A diagnostic challenge.

Ronchi A, Cozzolino I, Montella M, Vicidomini G, Morgillo F, Della Corte CM, Franco R, Accardo M.

Cytopathology. 2018 Apr;29(2):205-207. doi: 10.1111/cyt.12498. Epub 2017 Nov 21. No abstract available.

PMID:
29159961
24.

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.

Napolitano S, Martini G, Martinelli E, Della Corte CM, Morgillo F, Belli V, Cardone C, Matrone N, Ciardiello F, Troiani T.

Oncotarget. 2017 Aug 2;8(47):82773-82783. doi: 10.18632/oncotarget.19797. eCollection 2017 Oct 10.

25.

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M.

Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.

26.

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer.

Belli V, Sforza V, Cardone C, Martinelli E, Barra G, Matrone N, Napolitano S, Morgillo F, Tuccillo C, Federico A, Dallio M, Loguercio C, Gravina AG, De Palma R, Ciardiello F, Troiani T.

Oncotarget. 2017 Aug 7;8(40):68305-68316. doi: 10.18632/oncotarget.20054. eCollection 2017 Sep 15.

27.

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.

Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T.

Oncotarget. 2017 Jun 27;8(40):67592-67604. doi: 10.18632/oncotarget.18749. eCollection 2017 Sep 15.

28.

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.

Morgillo F, Amendola G, Della Corte CM, Giacomelli C, Botta L, Di Maro S, Messere A, Ciaramella V, Taliani S, Marinelli L, Trincavelli ML, Martini C, Novellino E, Ciardiello F, Cosconati S.

J Med Chem. 2017 Sep 14;60(17):7447-7458. doi: 10.1021/acs.jmedchem.7b00794. Epub 2017 Aug 22.

PMID:
28787156
29.

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.

Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E.

World J Gastroenterol. 2017 Jul 14;23(26):4675-4688. doi: 10.3748/wjg.v23.i26.4675. Review.

30.

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.

Morgillo F, Fasano M, Della Corte CM, Sasso FC, Papaccio F, Viscardi G, Esposito G, Di Liello R, Normanno N, Capuano A, Berrino L, Vicidomini G, Fiorelli A, Santini M, Ciardiello F.

ESMO Open. 2017 May 2;2(2):e000132. doi: 10.1136/esmoopen-2016-000132. eCollection 2017.

31.

Implication of the Hedgehog pathway in hepatocellular carcinoma.

Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F.

World J Gastroenterol. 2017 Jun 28;23(24):4330-4340. doi: 10.3748/wjg.v23.i24.4330. Review.

32.

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.

Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.

Oncotarget. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479.

33.

Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report.

Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, De Vita F.

Oncol Lett. 2017 Feb;13(2):979-983. doi: 10.3892/ol.2016.5523. Epub 2016 Dec 20.

34.

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.

Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F.

Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18.

35.

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.

Martinelli E, Morgillo F, Troiani T, Ciardiello F.

Cancer Treat Rev. 2017 Feb;53:61-69. doi: 10.1016/j.ctrv.2016.12.001. Epub 2016 Dec 30. Review.

PMID:
28073102
36.

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F.

ESMO Open. 2016 Sep 16;1(5):e000088. eCollection 2016. Review.

37.

Mechanisms of resistance to EGFR-targeted drugs: lung cancer.

Morgillo F, Della Corte CM, Fasano M, Ciardiello F.

ESMO Open. 2016 May 11;1(3):e000060. eCollection 2016. Review.

38.

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis.

Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, Iovino F, Romano C, Morgillo F, Mosca L, Diadema MR, Lieto E, Procaccini E, De Vita F, Ciardiello F.

ESMO Open. 2016 Mar 7;1(2):e000038. eCollection 2016.

39.

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

Califano R, Kerr K, Morgan RD, Lo Russo G, Garassino M, Morgillo F, Rossi A.

Curr Oncol Rep. 2016 Sep;18(9):59. doi: 10.1007/s11912-016-0544-7. Review.

PMID:
27484062
40.

Therapies in the pipeline for small-cell lung cancer.

Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R.

Br Med Bull. 2016 Sep;119(1):37-48. doi: 10.1093/bmb/ldw022. Epub 2016 Jun 20. Review.

PMID:
27325208
41.

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Gridelli C, Rossi A, Ciardiello F, De Marinis F, Crinò L, Morabito A, Morgillo F, Montanino A, Daniele G, Piccirillo MC, Normanno N, Gallo C, Perrone F.

Clin Lung Cancer. 2016 Sep;17(5):461-465. doi: 10.1016/j.cllc.2016.04.001. Epub 2016 Apr 22.

PMID:
27209164
42.

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.

Oncotarget. 2016 Jan 26;7(4):4265-78. doi: 10.18632/oncotarget.6559.

43.

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F.

Clin Cancer Res. 2015 Oct 15;21(20):4686-97. doi: 10.1158/1078-0432.CCR-14-3319. Epub 2015 Jun 29.

44.

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F.

J Thorac Oncol. 2015 Aug;10(8):1133-41. doi: 10.1097/JTO.0000000000000589.

45.

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.

Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N, Vitagliano D, Morgillo F, Fenizia F, Lambiase M, Formisano L, Bianco R, Ciardiello D, Ciardiello F.

Clin Cancer Res. 2015 Sep 15;21(18):4153-64. doi: 10.1158/1078-0432.CCR-15-0211. Epub 2015 May 27.

46.

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Califano R, Morgillo F, De Mello RA, Mountzios G.

Ann Transl Med. 2015 Apr;3(6):81. doi: 10.3978/j.issn.2305-5839.2015.03.44. Review.

47.

AXL is an oncotarget in human colorectal cancer.

Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, Liotti F, Nappi A, Bianco R, Berrino L, Ciuffreda LP, Ciardiello D, Iaffaioli V, Botti G, Ferraiolo F, Ciardiello F.

Oncotarget. 2015 Sep 15;6(27):23281-96.

48.

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F, Troiani T.

Clin Cancer Res. 2015 Jul 1;21(13):2975-83. doi: 10.1158/1078-0432.CCR-15-0020. Epub 2015 Apr 2.

49.

Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.

Della Corte CM, Fasano M, Papaccio F, Ciardiello F, Morgillo F.

Biomedicines. 2014 Nov 25;2(4):345-358. doi: 10.3390/biomedicines2040345. Review.

50.

A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.

Fasano M, Della Corte CM, Capuano A, Sasso FC, Papaccio F, Berrino L, Ciardiello F, Morgillo F.

Clin Lung Cancer. 2015 Jan;16(1):57-9. doi: 10.1016/j.cllc.2014.06.010. Epub 2014 Aug 17.

PMID:
25242667

Supplemental Content

Loading ...
Support Center